Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

KLRS stock hub

Kalaris Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

KLRSis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

116.8M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

KLRS

In the news

Latest news · KLRS

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-308.1

P25 -105.6P50 -46.5P75 -3.1

ROIC-116.4

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All KLRS market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

167

Groups with data

Currency

USD

Showing 167 of 167 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001754068
Company name	Kalaris Therapeutics, Inc.
Country	United States
Country code	US
Cusip	482929106
Employees	20
Enterprise value	$266,838
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US4829291065
Last refreshed	2026-05-10
Market cap	$116.8M
Market cap category	Micro-Cap
Price	$5.08
Price currency	USD
Sector	Healthcare
Sic	2836
Symbol	KLRS
Website	https://kalaristx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-37.19%
FCF yield	-33.02%
P/B ratio	1.48x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-43.4M
Net Income Growth Quarters	2%
Net Income Growth Years	2%
Profit Per Employee	$-2.2M
ROA	-45.11
ROCE	-41.2
ROE	-308.1
ROIC	-116.4

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	18.15%
EPS Growth Quarters	4
EPS Growth Years	1
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$121.7M
Cash	$118M
Current Assets	$118.8M
Current Liabilities	$9.7M
Debt	$1.4M
Debt Equity	$0.02
Equity	$78.8M
Interest Coverage	-28.33
Liabilities	$42.9M
Long Term Assets	$2.9M
Long Term Liabilities	$33.2M
Net Cash	$116.5M
Net Cash By Market Cap	$99.77
Net Debt Equity	$-1.48
Tangible Book Value	$78.8M
Tangible Book Value Per Share	$3.44

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	12.23
Net Working Capital	$-8.6M
Quick ratio	12.15
Working Capital	$109.1M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-1,042.87%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	18.14%
200-day SMA	6.41
50-day SMA	6.9
50-day SMA vs 200-day SMA	50over200
All Time High	12.9
All Time High Change	-60.62%
All Time High Date	2025-03-20
All Time Low	2.14
All Time Low Change	137.38%
All Time Low Date	2025-08-14
ATR	0.44
Beta1y	1.5
Beta2y	1.5
Ch YTD	-39.81
High	5.24
High52	11.88
High52 Date	2025-12-18
High52ch	-57.24%
Low	4.99
Low52	2.14
Low52 Date	2025-08-14
Low52ch	137.38%
Ma50ch	-26.38%
Price vs 200-day SMA	-20.72%
RSI	32.52
RSI Monthly	41.65
RSI Weekly	38.74
Sharpe ratio	0.65x
Sortino ratio	1.15
Total Return	-1,042.87%
Tr YTD	-39.81
Tr1m	-21.36%
Tr1w	-6.96%
Tr3m	-39.09%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	4
Analyst Count Top	2
Analyst Price Target Top	$19.5
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.52
Operating Income	$-46.2M
Price target	$19
Price Target Change	$274
Price Target Change Top	$284

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	6,371,556%
Float Percent	27.71%
Net Borrowing	7,500,000
Shares Insiders	6.23%
Shares Institutions	16.71%
Shares Out	22,992,291
Shares Qo Q	4.02%
Shares Yo Y	1,042.87%
Short Float	13.23%
Short Ratio	10.62
Short Shares	3.67

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-40.5M
Average Volume	93,484.5x
Bv Per Share	3.44
CAPEX	$-200,000
Ch1m	-21.36
Ch1w	-6.96
Ch1y	18.14
Ch3m	-39.09
Ch6m	6.95
Change	-1.36%
Change From Open	-1.74
Close	5.15
Days Gap	0.39
Depreciation Amortization	13,000
Dollar Volume	210,286.6
Earnings Date	2026-05-13
Earnings Time	bmo
EBIT	$-46.2M
EBITDA	$-46.1M
EPS	$-2.85
F Score	2
FCF	$-38.6M
FCF EV Yield	-14,454.46x
FCF Per Share	$-1.68
Financing CF	155,007,000
Fiscal Year End	December
Founded	2,019
Investing CF	-19,723,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-17
Last Report Date	2025-12-31
Last Split Type	Never
Last10k Filing Date	2026-03-17
Ma150	7.31
Ma150ch	-30.54%
Ma20	5.83
Ma20ch	-12.86%
Net CF	96,914,000
Next Earnings Date	2026-05-22
Open	5.17
Optionable	No
Position In Range	36
Post Close	5.08
Postmarket Change Percent	-2.36
Postmarket Price	$4.96
Ppne	1,475,000
Price Date	2026-05-08
Ptbv Ratio	1.48
Relative Volume	0.44x
Share Based Comp	1,936,000
Tr6m	6.95%
Us State	New Jersey
Volume	41,395

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does KLRS pay a dividend?

Capital-return profile for this ticker.

Performance

KLRS stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns KLRS?

Insider, institutional, and short-interest positioning.

Institutional ownership

+16.7%

Float: +27.7% of shares outstanding

Insider ownership

+6.2%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

KLRS momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

32.5

Neutral momentum band

Price vs 200-day MA

-20.7%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

0.65

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About KLRS

Hub-level FAQ points readers to the deeper analysis pages.

What is the current KLRS stock rating?

Kalaris Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full KLRS analysis?

The full report lives at /stocks/KLRS/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for KLRS?

The latest report frames KLRS around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the KLRS page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.